Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

In this case report, a novel heterozygous mutation in the insulin receptor gene was identified in an adolescent girl with type A insulin resistance syndrome, characterized by excessive hair growth and skin changes, and her mother.

This study demonstrates that spatially resolved IR and Raman imaging can effectively reveal the molecular structure and composition of untreated human hair, providing insights into its chemistry and structural integrity.

This study found that IBA-1-immunopositive macrophages in rat skin during wound healing show varied morphometric characteristics and peak in numbers at 2, 6, and 15 days post-injury.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study found that individuals with alopecia areata had significantly higher serum levels of retinol-binding protein 4 and increased IgG immunoreactivity against it, suggesting a role in the disease's pathogenesis.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This case report describes a 7-year-old girl who developed radiation-induced alopecia after a neurointerventional procedure, with dermoscopy revealing specific hair and scalp patterns that helped diagnose this rare complication. The findings highlight the importance of dermoscopy in distinguishing RIA from other alopecic disorders in children.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Radiation-induced hair loss may be caused by hair growth stopping and inflammation in blood vessels.

In this study, researchers used Mendelian randomization to find a significant genetic association between rheumatoid arthritis and an increased risk of alopecia areata, suggesting RA patients should be vigilant for potential AA development.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This study found that specific genetic variations in the IRF2BP2 gene influence fleece structure in sheep, with one variant completely determining coat type and another significantly modifying fiber characteristics, providing valuable insights for improving fleece quality through selective breeding.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that pulsed infrared diode laser therapy (904 nm) was effective in promoting hair regrowth in 94% of patients with resistant patches of alopecia areata.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

In this study, researchers reported that the Pinkie mutation in mice, affecting RXRa activity, leads to skewed Th1 development and suggests RXRa's role in Th2 differentiation, impacting immune responses.